Primidone in the long-term treatment of essential tremor: A prospective study with computerized quantitative analysis

E. Sasso, E. Perucca, R. Fava, S. Calzetti

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The long-term efficacy of primidone (375-750 mg/day) in essential tremor was evaluated prospectively in 11 patients who had shown a favorable response to 4-week treatment with the drug under placebo-controlled conditions. On accelerometric evaluation, the magnitude of tremor after 3, 6, and 12 months on primidone was still significantly reduced compared with the initial placebo period. After discontinuation of primidone, tremor amplitude reverted to the placebo levels. Some loss of efficacy during long-term administration, however, was suggested by the results of self-assessment, physicians' assessment, and performance tests. Three patients discontinued prematurely the drug because the sedative effects outweighed the potential therapeutic benefit. Side effects (especially drowsiness and sedation) were common at 4 weeks and 3 months but tended to subside thereafter. It is concluded that primidone retains at least part of its tremorolytic effect for up to 1 year, although the overall clinical benefit is limited in most patients.

Original languageEnglish
Pages (from-to)67-76
Number of pages10
JournalClinical Neuropharmacology
Volume13
Issue number1
Publication statusPublished - 1990

Fingerprint

Primidone
Essential Tremor
Prospective Studies
Placebos
Tremor
Sleep Stages
Therapeutics
Hypnotics and Sedatives
Pharmaceutical Preparations
Physicians

Keywords

  • Essential tremor
  • Long-term treatment
  • Primidone

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Primidone in the long-term treatment of essential tremor : A prospective study with computerized quantitative analysis. / Sasso, E.; Perucca, E.; Fava, R.; Calzetti, S.

In: Clinical Neuropharmacology, Vol. 13, No. 1, 1990, p. 67-76.

Research output: Contribution to journalArticle

@article{b2ae5c8e03064e96bc7b815f6afa113e,
title = "Primidone in the long-term treatment of essential tremor: A prospective study with computerized quantitative analysis",
abstract = "The long-term efficacy of primidone (375-750 mg/day) in essential tremor was evaluated prospectively in 11 patients who had shown a favorable response to 4-week treatment with the drug under placebo-controlled conditions. On accelerometric evaluation, the magnitude of tremor after 3, 6, and 12 months on primidone was still significantly reduced compared with the initial placebo period. After discontinuation of primidone, tremor amplitude reverted to the placebo levels. Some loss of efficacy during long-term administration, however, was suggested by the results of self-assessment, physicians' assessment, and performance tests. Three patients discontinued prematurely the drug because the sedative effects outweighed the potential therapeutic benefit. Side effects (especially drowsiness and sedation) were common at 4 weeks and 3 months but tended to subside thereafter. It is concluded that primidone retains at least part of its tremorolytic effect for up to 1 year, although the overall clinical benefit is limited in most patients.",
keywords = "Essential tremor, Long-term treatment, Primidone",
author = "E. Sasso and E. Perucca and R. Fava and S. Calzetti",
year = "1990",
language = "English",
volume = "13",
pages = "67--76",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Primidone in the long-term treatment of essential tremor

T2 - A prospective study with computerized quantitative analysis

AU - Sasso, E.

AU - Perucca, E.

AU - Fava, R.

AU - Calzetti, S.

PY - 1990

Y1 - 1990

N2 - The long-term efficacy of primidone (375-750 mg/day) in essential tremor was evaluated prospectively in 11 patients who had shown a favorable response to 4-week treatment with the drug under placebo-controlled conditions. On accelerometric evaluation, the magnitude of tremor after 3, 6, and 12 months on primidone was still significantly reduced compared with the initial placebo period. After discontinuation of primidone, tremor amplitude reverted to the placebo levels. Some loss of efficacy during long-term administration, however, was suggested by the results of self-assessment, physicians' assessment, and performance tests. Three patients discontinued prematurely the drug because the sedative effects outweighed the potential therapeutic benefit. Side effects (especially drowsiness and sedation) were common at 4 weeks and 3 months but tended to subside thereafter. It is concluded that primidone retains at least part of its tremorolytic effect for up to 1 year, although the overall clinical benefit is limited in most patients.

AB - The long-term efficacy of primidone (375-750 mg/day) in essential tremor was evaluated prospectively in 11 patients who had shown a favorable response to 4-week treatment with the drug under placebo-controlled conditions. On accelerometric evaluation, the magnitude of tremor after 3, 6, and 12 months on primidone was still significantly reduced compared with the initial placebo period. After discontinuation of primidone, tremor amplitude reverted to the placebo levels. Some loss of efficacy during long-term administration, however, was suggested by the results of self-assessment, physicians' assessment, and performance tests. Three patients discontinued prematurely the drug because the sedative effects outweighed the potential therapeutic benefit. Side effects (especially drowsiness and sedation) were common at 4 weeks and 3 months but tended to subside thereafter. It is concluded that primidone retains at least part of its tremorolytic effect for up to 1 year, although the overall clinical benefit is limited in most patients.

KW - Essential tremor

KW - Long-term treatment

KW - Primidone

UR - http://www.scopus.com/inward/record.url?scp=0025156925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025156925&partnerID=8YFLogxK

M3 - Article

C2 - 2306749

AN - SCOPUS:0025156925

VL - 13

SP - 67

EP - 76

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -